Epstein-Barr Virus-Associated Primary Central Nervous System Lymphoma in the Japanese Population

被引：21

作者：

Kitai, Ryuhei ^{[1
]}

Matsuda, Ken ^{[1
]}

Adachi, Erika ^{[1
]}

Saito, Yasushi ^{[1
]}

Nakajima, Tsuyoshi ^{[1
]}

Takeuchi, Hiroaki ^{[1
]}

Sato, Kazufumi ^{[1
]}

Imamura, Yoshiaki ^{[2
]}

Kubota, Toshihiko ^{[1
]}

机构：

[1] Univ Fukui, Fac Med Sci, Dept Neurosurg, Eiheiji, Fukui 9101193, Japan

[2] Univ Fukui Hosp, Div Surg Pathol, Fukui, Japan

来源：

NEUROLOGIA MEDICO-CHIRURGICA | 2010年 / 50卷 / 02期

关键词：

Epstein-Barr virus; Japan; immunocompromised patient; primary central nervous system lymphoma; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NON-HODGKINS-LYMPHOMA; BRAIN LYMPHOMA; EBV INFECTION; IMMUNOCOMPETENT; HYBRIDIZATION; CHEMOTHERAPY; INDIVIDUALS; CARCINOMAS; EXPRESSION;

D O I：

10.2176/nmc.50.114

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The incidence of Epstein-Barr virus (EBV)-associated primary central nervous system (CNS) lymphoma in Japan was assessed using in situ hybridization of EBV-encoded small ribonucleic acid-1 (EBER-1) to identify the presence of EBV in 22 cases of formalin-fixed and paraffin-embedded primary CNS lymphoma. All cases were B-cell lymphoma. EBER-1 expression was observed in the nuclei of 3 of 22 primary CNS lymphoma cases (13.6%). The incidence of EBV-positive lymphoma in Japanese cases is higher than previously reported from Western countries. Patients with EBV-positive primary CNS lymphoma showed shorter survival than those with negative tumors (median 4 months vs. 26 months). EBER-1 in situ hybridization for the detection of EBV infection is rapid and reliable. Infrequent association suggests a different pathogenetic mechanism in the evolution of these tumors. Geographical differences in the incidence of EBV-associated primary CNS lymphoma may reflect epidemiological factors.

引用

页码：114 / 118

页数：5

共 34 条

[11] PRIMARY CEREBRAL LYMPHOMA - A STUDY OF 47 CASES PROBED FOR EPSTEIN-BARR-VIRUS GENOME [J].

GEDDES, JF ;

BHATTACHARJEE, MB ;

SAVAGE, K ;

SCARAVILLI, F ;

MCLAUGHLIN, JE .

JOURNAL OF CLINICAL PATHOLOGY, 1992, 45 (07) :587-590

[12] Molecular diagnosis of Epstein-Barr virus-related diseases [J].

Gulley, ML .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2001, 3 (01) :1-10

[13]

HAMILTONDUTOIT SJ, 1993, BLOOD, V82, P619

[14] Anti-CD20 monoclonal antibody (Rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement [J].

Hänel, M ;

Fiedler, F ;

Thorns, C .

ONKOLOGIE, 2001, 24 (05) :491-494

[15] Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanese population with a high childhood incidence of asymptomatic primary EBV infection [J].

Harada, S ;

Kamata, Y ;

Ishii, Y ;

Eda, H ;

Kitamura, R ;

Obayashi, M ;

Ito, S ;

Ban, F ;

Kuranari, J ;

Nakajima, H ;

Kuze, T ;

Hayashi, M ;

Okabe, N ;

Senpuku, H ;

Miyasaka, N ;

Nakamura, Y ;

Kanegane, H ;

Yanagi, K .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (01) :123-130

[16]

Hirose Y, 1998, INT J HEMATOL, V67, P165

[17]

ITOYAMA T, 1994, CANCER-AM CANCER SOC, V73, P455, DOI 10.1002/1097-0142(19940115)73:2<455::AID-CNCR2820730234>3.0.CO

[18]

2-0

[19] Is EBV persistence in vivo a model for B cell homeostasis? [J].

Khan, G ;

Miyashita, EM ;

Yang, B ;

Babcock, GJ ;

ThorleyLawson, DA .

IMMUNITY, 1996, 5 (02) :173-179

[20]

KLEINHUES P, 1997, PATHOLOGY GENETICS T, P154

← 1 2 3 4 →